Noninvasive diagnosis of significant liver inflammation in patients with chronic hepatitis B in the indeterminate phase

References

• Jeng W, Papatheodoridis G, AJL L, et al. Hepatitis B. Lancet. 2023;401(10381):1039–9. doi: 10.1016/s0140-6736(22)01468-4
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–1599. doi: 10.1002/hep.29800
   PubMed Web of Science ®Google Scholar
• Lampertico P, Agarwal K, Berg T, et al. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. Hepatol. 2017;67(2):370–398. doi: 10.1016/j.jhep.2017.03.021
   Web of Science ®Google Scholar
• Hsu Y-N, Pan CQ, Abbasi A, et al. Clinical presentation and disease phases of chronic hepatitis B using conventional versus modified ALT criteria in Asian Americans. Dig Dis Sci. 2014;59:865–871. doi: 10.1007/s10620-014-3054-1
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Lombardero M, Teckman J, et al. Determination of hepatitis B phenotype using biochemical and serological markers. J Viral Hepat. 2017;24:320–329. doi: 10.1111/jvh.12643
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98. doi: 10.1007/s12072-015-9675-4
   PubMed Web of Science ®Google Scholar
• Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010;53:1013–1021. doi: 10.1016/j.jhep.2010.05.035
   PubMed Web of Science ®Google Scholar
• Alboraie M, Khairy M, Elsharkawy M, et al. Value of E gy- S core in diagnosis of significant, advanced hepatic fibrosis and cirrhosis compared to aspartate aminotransferase-to-platelet ratio index, FIB -4 and F orns’ index in chronic hepatitis C virus. Hepatol Res. 2015;45(5):560–570. doi: 10.1111/hepr.12385
   PubMed Web of Science ®Google Scholar
• Xiao G, Yang J, Yan L. Comparison of Diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61:292–302. doi: 10.1002/hep.27382
   PubMed Web of Science ®Google Scholar
• Lin C-L, Liu C-H, Wang C-C, et al. Serum biomarkers predictive of significant fibrosis and cirrhosis in chronic hepatitis B. J Clin Gastroenterol. 2015;49:705–713. doi: 10.1097/mcg.0000000000000250
   PubMed Web of Science ®Google Scholar
• Duan M, Chi X, Xiao H, et al. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B. Hepatol Int. 2021;15(2):318–327. doi: 10.1007/s12072-021-10153-2
   PubMed Web of Science ®Google Scholar
• Liu J, Wang J, Yan X, et al. Presence of liver inflammation in Asian patients with chronic hepatitis B with normal ALT and detectable HBV DNA in absence of liver fibrosis. Hepatol Commun. 2022;6(4):855–866. doi: 10.1002/hep4.1859
   PubMed Web of Science ®Google Scholar
• Wang H, Ru GQ, Yan R, et al. Histologic disease in Chinese chronic hepatitis B patients with low viral loads and persistently normal alanine aminotransferase levels. J Clin Gastroenterol. 2016;50:790–796. doi: 10.1097/mcg.0000000000000544
   PubMed Web of Science ®Google Scholar
• Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372–374. doi: 10.1016/0168-8278(91)90084-o
   PubMed Web of Science ®Google Scholar
• Yao K, Liu J, Wang J, et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone. J Viral Hepat. 2021;28:1025–1033. doi: 10.1111/jvh.13511
   PubMedGoogle Scholar
• Teng W, Chang T-T, Yang H-I, et al. Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines. Hepatol Int. 2021;15(6):1421–1430. doi: 10.1007/s12072-021-10263-x
   PubMed Web of Science ®Google Scholar
• Wang J, Yan X, Zhu L, et al. Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone. Aliment Pharmacol Ther. 2023;57:464–474. doi: 10.1111/apt.17272
   PubMed Web of Science ®Google Scholar
• Bonacci M, Lens S, Mariño Z, et al. Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the grey zone. Aliment Pharmacol Ther. 2018;47:1397–1408. doi: 10.1111/apt.14613
   PubMed Web of Science ®Google Scholar
• Huang DQ, Li X, Le MH, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase. Clin Gastroenterol Hepatol. doi: 10.1016/j.cgh.2021.01.019
   Web of Science ®Google Scholar
• Gui HL, Wang H, Yang YH, et al. Significant histopathology in Chinese chronic hepatitis B patients with persistently high–normal alanine aminotransferase. J Viral Hepat. 2010;17(s1):44–50. doi: 10.1111/j.1365-2893.2010.01270.x
   PubMedGoogle Scholar
• Wang J, Xia J, Yan X, et al. The gamma-glutamyl transpeptidase to platelet ratio predicts liver inflammation in chronic hepatitis B with normal or mildly elevated alanine transaminase. Clin Res Hepatol Gastroenterol. 2020;44:913–922. doi: 10.1016/j.clinre.2020.01.011
   PubMed Web of Science ®Google Scholar
• Chinese Society of Infectious Diseases CMA, Chinese Society of Hepatology CMA. The guidelines of prevention and treatment for chronic hepatitis B (2019 version). Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi =. Chinese J Hepat. 2019;27(12):938–961. doi: 10.3760/cma.j.issn.1007-3418.2019.12.007
   PubMedGoogle Scholar
• Chang X, Wang J, Chen Y, et al. A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection. EBioMedicine. 2021;67. doi: 10.1016/j.ebiom.2021.103389
   Web of Science ®Google Scholar
• Li X, Xing Y, Zhou D, et al. A non-invasive model for predicting liver inflammation in chronic hepatitis B patients with normal serum alanine aminotransferase levels. Front Med (Lausanne). 2021;8:688091. doi: 10.3389/fmed.2021.688091
   PubMed Web of Science ®Google Scholar
• Xie Y, Yi W, Zhang L, et al. Evaluation of a logistic regression model for predicting liver necroinflammation in hepatitis B e antigen-negative chronic hepatitis B patients with normal and minimally increased alanine aminotransferase levels. J Viral Hepat. 2019;26(S1):42–49. doi: 10.1111/jvh.13163
   PubMedGoogle Scholar
• Chen S, HJFim H. Clinical non-invasive model to predict liver inflammation in chronic hepatitis B with alanine aminotransferase ≤ 2 upper limit of normal. Front Med. 2021;8:661725. doi: 10.3389/fmed.2021.661725
   Web of Science ®Google Scholar
• Wang J, Xia J, Zhang R, et al. A novel index using routine clinical parameters for predicting significant liver inflammation in chronic hepatitis B. J Viral Hepat. 2018;25:1151–1160. doi: 10.1111/jvh.12925
   PubMed Web of Science ®Google Scholar
• Eminler AT, Irak K, Ayyildiz T, et al. The relation between liver histopathology and GGT levels in viral hepatitis: more important in hepatitis B. Turk J Gastroenterol. 2014;25:411–415. doi: 10.5152/tjg.2014.3693
   PubMed Web of Science ®Google Scholar
• Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112:18–35. doi: 10.1038/ajg.2016.517
   PubMed Web of Science ®Google Scholar